we quantified a time course of subjective insomnia and found its duration again to be measured more in weeks than in days. The duration is consistent with the two to four weeks of anxiety after withdrawal of benzodiazepines. 7 8 Drugs that are more rapidly eliminated give rise to an earlier rebound,6 which would explain why lormetazepam (with a half life of only 10 hours9) gave rise to a peak of rebound on the second night after withdrawal, whereas nitrazepam (with a half life of active metabolites of about 30 hours' 0) gave a peak on the fourth night. This interpretation is consistent with electroencephalographic signs of persistence of nitrazepam as late as three nights after withdrawal of a nightly dose of 15 mg. 5 Our findings suggest that it is desirable to prescribe benzodiazepines when an eventual reduction in life's problems is foreseen, with the aim of stopping the drugs coincident with that reduction; the patient should be told that a period of disturbed sleep may be expected after withdrawal.
We thank Mr K Fichte, Dr Susan Allen, Dr H Ott, Dr Controlled trial of slow-release aminophylline in childhood asthma: are short-term trials valid?
NICOLA WILSON, MICHAEL SILVERMAN Abstract Slow-release aminophylline, although widely used for the prophylaxis of childhood asthma, has had only limited formal assessment. A four-month double-blind cross-over trial of slow-release aminophylline (14 mg/kg twice daily) was carried out in 24 children with perennial asthma. Satisfactory serum theophylline concentrations were obtained in 17 children, with few side effects. There was a significant improvement in mild daytime and night-time symptoms. The incidence of more severe symptoms was unaffected. Treatment did not improve the mean peak expiratory flow or reduce the incidence of use of bronchodilators. It is concluded that slow-release aminophylline has a place in the prophylaxis of perennial childhood asthma but is unsuitable for children who suffer from severe attacks. The cross-over trial design has severe limitations.
Introduction
In recent years it has become common practice to treat children with moderately severe perennial asthma with continuous prophylaxis. Methylxanthines have been widely used in this way, particularly in the USA, where they are often the first line of treatment. Sustained-release oral preparations have the important advantage that only twice-daily administration is needed to give fairly stable serum theophylline concentrations over 24 hours.' The clinical value in chronic childhood asthma of conventional treatment with oral theophylline has been shown in controlled clinical trials.2 3 We designed the present study to show the value of an oral preparation of slow-release aminophylline in a group of children considered to need continuous prophylactic treatment for their asthma.
Methods
Trial design-The study was in the form of a double-blind crossover trial with active slow-release aminophylline and placebo given in random order, each for an eight-week period. A run-up period was not obligatory, although most patients underwent at least one month of close monitoring before entry to establish their need for continuous prophylaxis. There was no break between the first and second eightweek periods. Patients were instructed to take their trial drugs after food, twice daily, with a 12-hour interval in between. The slowrelease aminophylline (Phyllocontin, Napp Laboratories) was prescribed as a combination of 100 mg and 225 mg tablets to give a dose of about 14 mg/kg. An indistinguishable placebo preparation was given during the control period. Additional beta-agonists were taken as required.
Patient selection-Children of school age who were able to use a peak flow meter and to swallow tablets and whose parents could reliably fill in a daily record card were selected if they were considered to require continuous treatment because of frequent symptoms (occurring on at least 10 days each month) or because they were already taking some form of daily non-steroid prophylactic treatment.
Parental consent was obtained and the project approved by the research ethics committee of the hospital.
Patient evaluation-The children were seen every four weeks during the 16-week study. Blood was taken for estimation of serum theophylline concentration4 at least once during each drug period and any side effects noted. At home symptoms (cough and wheeze separately recorded for day and night) and twice-daily measurements of peak flow (the best of three readings using a Wright Minimeter, Airmed) were recorded on the daily record card (diary). Patients (To avoid spuriously high results the highest peak expiratory flow during the four-month trial period with four readings of equal or higher value-that is, the fifth in rank-was accepted.)
Results
Forty children entered the trial, but only 24 completed the full period satisfactorily. Eight children were withdrawn because of poor record keeping, which was a reflection of parental compliance locally. Three children were withdrawn because they rejected the flavour of the tablets and two because of side effects of theophylline. Of the three other children withdrawn, who had sufficiently severe attacks of asthma to require decoding, two were found to be taking placebo and one slow-release aminophylline.
Side effects-Five of the original 40 children were withdrawn from the trial because of the ill effects of theophylline (including its bitter taste). In those who completed the trial side effects were more common during treatment with slow-release aminophylline (table I) .
Serum theophylline concentrations-The overall mean dose of slowrelease aminophylline (excluding the dose in the two postpubertal children, who needed much lower doses to provide therapeutic concentrations) was 13-3 (± SE 0-28) mg/kg. This produced a mean serum theophylline concentration of 13 6 (+1-38) mg/l in blood sampled 2-8 (±0-16) hours after the preceding dose (table II) . (The concentration in case 23 was excluded as it was thought to reflect failure to take the drug.)
Subjective assessment-Night-time symptoms and daytime diary scores were significantly lower when patients took slow-release aminophylline compared with placebo. The number of symptom-free days and the mean use of beta-agonists, however, were no different (table III) . Analysed in more detail, the diary scores clearly showed that severe symptoms (score 3) were not less common during active treatment, whereas milder symptoms (scores 1 and 2) were significantly reduced (p < 0-02; table IV). Objective assessment-Morning and evening readings of peak expiratory flow varied independently of the drug taken when studied by analysis of variance (table III) . Individual analysis showed that six children had a significantly higher peak expiratory flow while taking active treatment and eight while taking placebo. During the trial there was a general improvement in mean peak expiratory flow, which was independent of treatment. The mean ± SEM peak flow expressed as a percentage of the predicted value in group A was 78-40±3-16% in the first two months (active treatment) and 81-54±+ (table III) . Period effect and treatment interaction-When the diary scores and readings of peak expiratory flow were looked at in each drug-order group (groups A and B) and the mean for each group compared for both halves of the trial there was a general tendency for all variables to improve with time (fig 1) . This time trend (period effect) was calculated by subtracting the mean difference between active and placebo treatments in group A from that in group B; it was significant for night-time and daytime symptoms (fig 1) as well as morning and evening readings of peak expiratory flow. An assumption in cross-over trials is that the treatment effect (the difference in response between active treatment and placebo) is the same in both halves of the trial. Although this was true for daytime symptoms, the mean treatment effect for night-time symptoms was large in the first half of the trial and negligible in the second (fig 1) , suggesting that the order in which the drugs were given might have affected the response (that is, there was interaction between treatment and period). Statistically, however, this was not quite significant, so that the cross-over design was valid. 865 alone before the trial and were included because they were considered to need additional treatment. The remaining 16 were already taking some form of long-term prophylaxis and were in a fairly stable clinical state. They had already met the clinical criteria for long-term prophylaxis.
Looking only at group mean values obscures the striking variation in symptoms that occurred in most of our subjects over the 16 weeks of the trial. This makes it difficult to assess the beneficial effect of slow-release aminophylline in an individual subject and makes controlled clinical trials essential in determining the protective effect of drugs in asthma. In fact, the larger the inherent variability the greater the numbers needed in a trial to show a treatment effect. With 24 subjects we would have expected to detect a treatment effect of at least 19 1/min 600 
Discussion
This study showed that slow-release aminophylline reduced symptoms in a group of children suffering from perennial asthma. In particular, mild symptoms were reduced by both day and night. In view of the steady improvement over the 16 weeks of the trial the clinical criteria on which the decision to start long-term prophylactic treatment was based may be called into question.
SERUM THEOPHYLLINE CONCENTRATIONS: SIDE EFFECTS
Prescribing at a standard dose of 14 mg/kg for prepubertal children produced acceptable serum theophylline concentrations in all but two subjects, one of whom had a potentially dangerous concentration (case 11): at the age of 11 she was nearing puberty. Caution is needed in prescribing theophylline preparations for teenagers, as the rate of elimination of the drug falls with age.7 The only postpubertal subjects (cases 2 and 12) needed much lower doses to produce therapeutic serum concentrations. The low concentration in case 23 probably reflected failure to take the drug.
The therapeutic range of serum theophylline concentrations is usually considered to be 10-20 mg/l. A serum concentration of 6 mg or more/l two hours after the dose was considered to be acceptable, as the peak concentration usually occurs two to six hours after ingestion' and there is a logarithmic relation between dose and response.8 One patient (case 5) was taking his maximum tolerated dose: a higher dose induced nausea.
Two children failed to complete the trial because of side effects of aminophylline, and two others who continued the drug after the trial had to stop taking it because of side effects. Up to 30%> of subjects in other trials have been unable to take methyl- fig 1) the effect was considerable. There was a striking difference between different variables in the pattern of response to treatment. The only objective variable, peak expiratory flow, provided the least conclusive results.
Not only was there a general tendency for the mean peak expiratory flow to improve during the course of the trial, but a great discrepancy was seen between the overall mean values in groups A and B. To see whether normalising the peak expiratory flow for height had unfairly weighted one group we plotted each child's maximum peak flow on a chart giving the predicted flow for height6 (fig 2) . In group B significantly more children had values of peak expiratory flow at about 2 SDs above the mean (p <0 05). Use of the minimeter might have resulted in an overreading of 51 1f but our impression is that in highly trained subjects the predicted values are too low, particularly in younger children. We have noticed in other trials too that mean values of peak expiratory flow are often within the normal 'range3 even when asthmatic symptoms are recorded.
OBJECTIVE VERSUS SUBJECTIVE DATA Despite symptomatic improvement the objective records of peak expiratory flow failed to distinguish between active and placebo treatment. This somewhat inconclusive result has sometimes been found in similar trials, and the question often asked is whether diary scores alone are sufficient evidence of improved control or whether the twice-daily readings of peak flow reflect the true state of affairs. The objective measurement of peak expiratory flow is thought to relate to large airway function and to be a good indicator of acute change in airways function. It may not, however, reflect small airways obstruction with consequent increase in residual volume, both of which may produce symptoms and may be slow in returning to normal after acute asthmatic attacks'2 and exercise-induced asthma.'3 The dissociation between symptoms and tests of lung function is made worse by the use of additional bronchodilators, taken whenever needed without allowance for the time of dosing in relation to the recording of peak expiratory flow.
In a study looking at airways obstruction induced by challenge with methacholine Rubinfield and Pain'4 found that 150( of patients had no symptoms when their forced expiratory volume in one second was less than 50°,, of predicted values. Paediatric trials deal mainly with parental perception of children's symptoms, adding further imprecision and thus rendering the correlation between objective and subjective variables even less good.
LONG-TERM PROPHYLAXIS IN CHILDHOOD ASTHMA
Since the advent of sodium cromoglycate children with perennial asthma are often prescribed long-term prophylactic treatment and advised that they must continue with it regularly, perhaps for many years. Continuous treatment is often started on the basis of dubious short-term improvement. The criteria for long-term prophylaxis need to be clearly defined before the much-needed long-term trials are carried out, particularly as more prophylactic agents become available. It is the considerable intrasubject variation in symptoms that makes such trials difficult to conduct and suggests that unvarying treatment given throughout the year may be inappropriate for many children.
We found that slow-release aminophylline does not affect the incidence of severe symptoms, and therefore it should not be prescribed on a long-term basis as prophylaxis against infrequent, severe attacks. We found that it reduces chronic mild symptoms in a group of asthmatic children as a whole, and in those subjects who did not suffer side effects it seemed to be a simple and effective prophylactic agent. Because of our detailed analysis our conclusions appear limited, in contrast to those of many studies in which marginal statistical benefits are emphasised.
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HEMLOCK. The common great Hemlock grows up with a green stalk, four or five feet high, or more, full of red spots sometimes, and at the joints very large winged leaves set at them, which are divided into many other winged leaves, one set against the other, dented about the edges, of a sad green colour, branched towards the top, where it is full of umbels of white flowers, and afterwards with whitish flat seed:
The root is long, white, and sometimes crooked, and hollow within. The whole plant, and every part, has a strong, heady, and ill-savoured scent, much offending the senses. It grows in all counties of this land, by walls and hedge-sides, in waste grounds and untilled places. It flowers and seeds in July, or thereabouts. Saturn claims dominion over this herb, yet I wonder why it may not be applied to the privities in a Priapism, or continual standing of the yard, it being very beneficial to that disease; I suppose, my author's judgment was first upon the opposite disposition of Saturn to Venus in those faculties, and therefore he forbade the applying of it to those parts, that it might not cause barrenness, or spoil the spirit procreative; which if it do, yet applied to the privities, it stops its lustful thoughts. Hemlock is exceedingly cold, and very dangerous, especially to be taken inwardly. It may safely be applied to inflammations, tumours and swellings in any part of the body (save the privy parts) as also to St Anthony's fire, wheals, pushes, and creeping ulcers that arise of hot sharp humours, by cooling and repelling the heat; the leaves bruised and laid to the brow or forehead are good for their eyes that are red and swollen; as also to take away a pin and web growing in the eye; this is a tried medicine: Take a small handful of this herb, and half so much bay salt, beaten together, and applied to the contrary wrist of the hand, for 24 hours, doth remove it in thrice dressing. If the root thereof be roasted under the embers, wrapped in double wet paper, until it be soft and tender, and then applied to the gout in the hands or fingers, it will quickly help this evil. If any through mistake eat the herb Hemlock instead of Parsley, or the roots instead of a Parsnip (both of which it is very like) whereby happens a kind of frenzy, or perturbation of the senses, as if they were stupid and drunk, the remedy is (as Pliny saith) to drink of the best and strongest pure wine, before it strikes to the heart, or Gentian put in wine, or a draught of vinegar, wherewith Tragus doth affirm, that he cured a woman that had eaten the root. (Nicholas Culpeper (1616-54) The Complete Herbal, 1850.)
